BioSpace News Archive

Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with certain existing and new investors.

Immunome, Inc. announced that it entered into a definitive asset purchase agreement with Atreca, Inc. to acquire a collection of antibody-related assets and materials.

Madryn Asset Management, LP, a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc., disclosed that the Transaction Committee of the Company’s Board of Directors did not pursue a substantive dialogue with Laboratory Corporation of America Holdings – one of the industry’s most logical strategics, with a $19 billion market capitalization – before recommending shareholders vote for the proposed merger with Standard BioTools Inc.

Ainos, Inc. announced that it is initiating the second phase of co-development of a volatile organic compound sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co.

SomaLogic, Inc., a leader in proteomics technology, issued the following statement in response to a press release issued by Madryn Asset Management, LP on December 26, 2023, regarding the pending merger with Standard BioTools.

Caliway Biopharmaceuticals announced that the company will present at the 25th IMCAS World Congress on 1-3 February 2024 in Paris, France.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023.

Cytokinetics, Incorporated announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten, an investigational medicine, in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Innovent Biologics, Inc. and Sanegene Bio USA Inc. announce that they have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen for the treatment of hypertension.